BR112017015093A2 - derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3 - Google Patents

derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3

Info

Publication number
BR112017015093A2
BR112017015093A2 BR112017015093-0A BR112017015093A BR112017015093A2 BR 112017015093 A2 BR112017015093 A2 BR 112017015093A2 BR 112017015093 A BR112017015093 A BR 112017015093A BR 112017015093 A2 BR112017015093 A2 BR 112017015093A2
Authority
BR
Brazil
Prior art keywords
receptor modulators
piperazine derivatives
cxcr3 receptor
hydroxyalkyl piperazine
hydroxyalkyl
Prior art date
Application number
BR112017015093-0A
Other languages
English (en)
Inventor
Caroff Eva
Meyer Emmanuel
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of BR112017015093A2 publication Critical patent/BR112017015093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a invenção refere-se aos compostos da fórmula (i) fórmula (i) em que n, x, r1 e r2 são tais como expostos na descrição; aos seus sais farmaceuticamente aceitáveis, e ao uso desses compostos como medicamentos, especialmente como moduladores do receptor cxcr3.
BR112017015093-0A 2015-01-15 2016-01-14 derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3 BR112017015093A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2015050696 2015-01-15
EPPCT/EP2015/050696 2015-01-15
PCT/EP2016/050645 WO2016113344A1 (en) 2015-01-15 2016-01-14 Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators

Publications (1)

Publication Number Publication Date
BR112017015093A2 true BR112017015093A2 (pt) 2018-04-17

Family

ID=55129886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015093-0A BR112017015093A2 (pt) 2015-01-15 2016-01-14 derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3

Country Status (38)

Country Link
US (1) US10053457B2 (pt)
EP (1) EP3245203B1 (pt)
JP (1) JP6337218B2 (pt)
KR (1) KR101967083B1 (pt)
CN (1) CN107250133B (pt)
AR (1) AR103414A1 (pt)
AU (1) AU2016207988B2 (pt)
BR (1) BR112017015093A2 (pt)
CA (1) CA2972952C (pt)
CL (1) CL2017001831A1 (pt)
CO (1) CO2017008156A2 (pt)
CY (1) CY1121361T1 (pt)
DK (1) DK3245203T3 (pt)
EA (1) EA032927B1 (pt)
ES (1) ES2709985T3 (pt)
HK (1) HK1246789B (pt)
HR (1) HRP20190024T1 (pt)
HU (1) HUE042559T2 (pt)
IL (1) IL253411B (pt)
LT (1) LT3245203T (pt)
MA (1) MA41337A (pt)
MX (1) MX2017009288A (pt)
MY (1) MY187614A (pt)
NZ (1) NZ734542A (pt)
PE (1) PE20171100A1 (pt)
PH (1) PH12017501280B1 (pt)
PL (1) PL3245203T3 (pt)
PT (1) PT3245203T (pt)
RS (1) RS58349B1 (pt)
SA (1) SA517381905B1 (pt)
SG (1) SG11201705617XA (pt)
SI (1) SI3245203T1 (pt)
TN (1) TN2017000278A1 (pt)
TR (1) TR201900680T4 (pt)
TW (1) TWI693221B (pt)
UA (1) UA119805C2 (pt)
WO (1) WO2016113344A1 (pt)
ZA (1) ZA201705486B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
PE20171100A1 (es) * 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2018011265A1 (en) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
WO2020060964A1 (en) * 2018-09-18 2020-03-26 Alxerion Biotech Corp. 1, 2, 4-oxadiazole derivatives and uses thereof
MX2023008659A (es) 2021-01-28 2023-08-01 Idorsia Pharmaceuticals Ltd Forma cristalina de un derivado de piperazinil-tiazol.
WO2024052445A1 (en) 2022-09-09 2024-03-14 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291619B2 (en) 2001-01-23 2007-11-06 Eli Lilly And Company Melanocortin receptor agonists
JP2004521117A (ja) 2001-01-23 2004-07-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン
WO2002070511A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
DE60328690D1 (de) 2002-06-12 2009-09-17 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
WO2006047277A2 (en) 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
JP2008530212A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
BRPI0607385A2 (pt) 2005-02-16 2009-09-01 Schering Corp piperazinas substituìdas heterocìclicas com atividade de antagonista de cxcr3
CN101213185A (zh) 2005-02-16 2008-07-02 先灵公司 具有cxcr3拮抗活性的吡啶基和苯基取代的哌嗪-哌啶
KR20070107060A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 피라지닐 치환된피페라진-피페리딘
JP2008530213A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ヘテロアリールで置換されたピラジニル−ピペラジン−ピペリジン
WO2006088920A1 (en) 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
WO2007002667A2 (en) 2005-06-22 2007-01-04 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
WO2007002742A1 (en) 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
EP1937666B1 (en) 2005-10-11 2012-02-22 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
UA94719C2 (ru) 2005-10-18 2011-06-10 Янссен Фармацевтика Н.В. Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
US20070126158A1 (en) 2005-12-01 2007-06-07 3M Innovative Properties Company Method of cleaning polymeric mold
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
EP1988900A2 (en) 2006-02-23 2008-11-12 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
BRPI0709035A2 (pt) 2006-03-21 2011-06-21 Schering Corp compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3
ES2389678T3 (es) 2006-04-20 2012-10-30 Janssen Pharmaceutica Nv Un inhibidor de la quinasa C-Kit para su uso en el tratamiento de tumores del estroma gastrointestinal o mastocitosis
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
CA2658417A1 (en) 2006-07-14 2008-01-17 Schering Corporation Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
JP2010513520A (ja) 2006-12-22 2010-04-30 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する複素環式化合物
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
US8420673B2 (en) 2007-01-25 2013-04-16 E I Du Pont De Nemours And Company Fungicidal amides
JP2010535711A (ja) 2007-08-03 2010-11-25 シェーリング コーポレイション 複素環式置換ピペラジンを用いる、ｃｘｃｒ３媒介性疾患の処置方法
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
US20110124867A1 (en) 2007-12-18 2011-05-26 Schering Corporation Process and intermediates for the Synthesis of heterocyclic Substituted Piperazines with CXCR3 Antagonist Activity
CN101970432B (zh) 2008-01-25 2014-05-28 杜邦公司 杀真菌杂环化合物
US20100286147A1 (en) 2008-01-25 2010-11-11 E.I. Dupont De Nemours And Company Fungicidal amides
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
CA2722775A1 (en) 2008-04-30 2009-11-05 Pierre Cristau Thiazol-4-carboxylic acid esters and thioesters as plant protection agents
JP5785495B2 (ja) 2008-10-01 2015-09-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 植物保護剤としてのヘテロシクリル置換チアゾール類
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
WO2010065579A2 (en) 2008-12-02 2010-06-10 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
BRPI0923366A2 (pt) 2008-12-11 2019-09-24 Bayer Cropscience Ag éteres e hodrazonas de oxima de tiazolila como agentes protetors de culturas.
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
CN102596943A (zh) 2009-08-12 2012-07-18 先正达参股股份有限公司 杀灭微生物杂环类化合物
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
CN102712634B (zh) 2009-10-30 2016-04-06 拜耳知识产权有限责任公司 杂芳基哌啶和杂芳基哌嗪衍生物
EP2516426B1 (de) 2009-12-21 2015-09-16 Bayer CropScience AG Bis(difluormethyl)pyrazole als fungizide
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
JP5960683B2 (ja) 2010-04-28 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺真菌剤としてのケトヘテロアリールピペリジンおよび−ピペラジン誘導体
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
BR112012026708A2 (pt) 2010-05-20 2015-09-22 Du Pont composto selecionado, composição fungicida e método para controlar doenças vegetais
WO2011147765A1 (de) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarbonsäure derivate als fungizide
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
CA2815716C (en) 2010-10-27 2019-06-11 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
CN103228645A (zh) 2010-11-25 2013-07-31 先正达参股股份有限公司 杀微生物杂环
US20130261154A1 (en) 2010-12-17 2013-10-03 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
CN103492380A (zh) 2011-02-01 2014-01-01 拜耳知识产权有限责任公司 作为杀真菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
BR112013020419A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag microbicidas derivados de pirazol
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US10004232B2 (en) 2011-09-15 2018-06-26 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
EP2768828A1 (en) 2011-10-18 2014-08-27 Syngenta Participations AG Microbiocidal pyrazole derivatives
US20140228372A1 (en) 2011-10-18 2014-08-14 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
PL2807153T3 (pl) 2012-01-25 2020-09-07 Novartis Ag Związki heterocykliczne i sposoby ich zastosowania
EP2809668B1 (en) * 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
IN2012DE00620A (pt) 2012-03-02 2015-08-21 Syngenta Participations Ag
EP2820015A1 (en) 2012-03-02 2015-01-07 Syngenta Participations AG Microbiocidal pyrazole derivatives
DK2855453T3 (en) * 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN104981457B (zh) 2012-12-11 2017-09-19 武田药品工业株式会社 杂环化合物
EP3013821B1 (en) 2013-06-24 2018-03-14 Bayer CropScience Aktiengesellschaft Piperidinecarboxylic acid derivatives as fungicides
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
US9718818B2 (en) 2013-08-22 2017-08-01 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
PE20171100A1 (es) * 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3

Also Published As

Publication number Publication date
MX2017009288A (es) 2017-10-11
DK3245203T3 (en) 2019-02-18
JP6337218B2 (ja) 2018-06-06
UA119805C2 (uk) 2019-08-12
MA41337A (fr) 2017-11-22
HUE042559T2 (hu) 2019-07-29
CA2972952A1 (en) 2016-07-21
ZA201705486B (en) 2019-06-26
PH12017501280A1 (en) 2018-01-15
CO2017008156A2 (es) 2017-11-30
CL2017001831A1 (es) 2018-05-11
EP3245203A1 (en) 2017-11-22
KR101967083B1 (ko) 2019-04-08
LT3245203T (lt) 2019-02-11
TR201900680T4 (tr) 2019-02-21
IL253411A0 (en) 2017-09-28
TW201632519A (zh) 2016-09-16
AU2016207988B2 (en) 2019-08-15
PH12017501280B1 (en) 2018-01-15
PL3245203T3 (pl) 2019-05-31
MY187614A (en) 2021-10-04
HRP20190024T1 (hr) 2019-02-22
US10053457B2 (en) 2018-08-21
JP2018502161A (ja) 2018-01-25
US20180009799A1 (en) 2018-01-11
CN107250133A (zh) 2017-10-13
PT3245203T (pt) 2019-02-08
AR103414A1 (es) 2017-05-10
IL253411B (en) 2020-08-31
WO2016113344A1 (en) 2016-07-21
SG11201705617XA (en) 2017-08-30
RS58349B1 (sr) 2019-03-29
HK1246789B (zh) 2019-11-22
EP3245203B1 (en) 2018-11-14
CA2972952C (en) 2021-01-05
NZ734542A (en) 2023-02-24
CN107250133B (zh) 2020-09-15
EA201791600A1 (ru) 2018-03-30
ES2709985T3 (es) 2019-04-22
TN2017000278A1 (en) 2019-01-16
KR20170102010A (ko) 2017-09-06
CY1121361T1 (el) 2020-05-29
AU2016207988A1 (en) 2017-08-31
SI3245203T1 (sl) 2019-03-29
SA517381905B1 (ar) 2021-04-01
PE20171100A1 (es) 2017-08-07
TWI693221B (zh) 2020-05-11
EA032927B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
BR112017015093A2 (pt) derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3
ECSP18090144A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112016022046A2 (pt) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
ECSP17082825A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP18053634A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112014030173A2 (pt) derivados de benzimidazol-prolina
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECSP18023286A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
BR112019001551A2 (pt) moduladores do receptor de piperidina cxcr7
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
BR112015022993A2 (pt) inibidores de jak2 e alk2 e métodos de uso dos mesmos
BR112017015116A2 (pt) derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR112015023161A8 (pt) derivados de piridin-4-ila
BR112014018714A8 (pt) Compostos de 4-(benzoimidazol-2-il)-tiazol e derivados de aza relacionados
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
BR112015030095A2 (pt) moduladores do receptor de cxcr7
BR112016001238A8 (pt) Derivados de 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona, seus usos e composição farmacêutica os compreendendo
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
BR112017023200A2 (pt) compostos de indolona e seu uso como moduladores do receptor de ampa
BR112016028315A8 (pt) Compostos de pirazol, composição farmacêutica, e, uso de um composto como bloqueador do canal de cálcio do tipo t
BR112017005179A8 (pt) Compostos triazol como bloqueadores dos canais de cálcio tipo t, uso dos mesmos, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]